Gawlik-Kotelnicka Oliwia, Sobczak Marharyta, Palma Joanna, Popławska Marta, Skonieczna-Żydecka Karolina, Plewka Maksymilian, Pawliczak Rafał, Strzelecki Dominik
Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz 92-216, Poland.
Department of Immunopathology, Division of Biomedical Science, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Comput Struct Biotechnol J. 2025 May 27;27:2275-2287. doi: 10.1016/j.csbj.2025.05.035. eCollection 2025.
Dysbiosis appears to be a significant contributor to the complex pathophysiology of mood disorders, and short-chain fatty acids (SCFAs), the main metabolites produced in the colon by bacterial fermentation, have been found to play a role in gut-brain communication. Probiotics were shown to be effective in managing and alleviating depressive symptoms, especially as an add-on protocol. This study aimed to assess the change in fecal SCFAs levels after supplementation with probiotics in patients with depression, depending on baseline antidepressant treatment.
This was a secondary analysis of a two-arm, parallel-group, randomized, double-blind, controlled trial. Data from 65 participants were analyzed. The intervention included probiotic formulation ( Rosell®-52 and Rosell®-175; R0052/R0175) or placebo over a 60-day period. Then, stratification was performed by the type of antidepressant medications. Fecal SCFAs were measured by the gas chromatography method. Pre-intervention socio-demographic, clinical, and laboratory data were assessed.
Probiotics used decreased the levels of isovaleric acid compared with placebo when administered with non-selective serotonin reuptake inhibitors antidepressants (non-SSRIs) with large effect size (p = .019, |r|=.653), but not when used with SSRIs (p = .572, |r|=.109) or applied alone (p = .404, |r|=.182). Isovalerate levels decreased as depression improved in the probiotic plus non-SSRIs group. Conclusions: R0052/R0175 as an add-on to non-SSRI antidepressants may offer antidepressant action partly through the decrease in isovaleric acid levels. More research with a larger sample size is needed to study SCFAs' role as a mediator of antidepressant action of both probiotics and medications. ClinicalTrials.gov identifier: NCT04756544.
肠道菌群失调似乎是导致情绪障碍复杂病理生理过程的一个重要因素，而短链脂肪酸（SCFAs）作为结肠中细菌发酵产生的主要代谢产物，已被发现参与肠脑通讯。益生菌已被证明在管理和缓解抑郁症状方面有效，尤其是作为一种辅助治疗方案。本研究旨在评估抑郁症患者补充益生菌后粪便SCFAs水平的变化，并分析其与基线抗抑郁治疗的关系。
这是一项双臂、平行组、随机、双盲、对照试验的二次分析。分析了65名参与者的数据。干预措施为在60天内服用益生菌制剂（罗伊氏乳杆菌Rosell®-52和嗜酸乳杆菌Rosell®-175；R0052/R0175）或安慰剂。然后，根据抗抑郁药物的类型进行分层。采用气相色谱法测量粪便SCFAs。评估干预前的社会人口统计学、临床和实验室数据。
与安慰剂相比，在与非选择性5-羟色胺再摄取抑制剂（非SSRIs）联合使用时，益生菌可降低异戊酸水平，效应量较大（p = 0.019，|r| = 0.653），但与SSRIs联合使用时（p = 0.572，|r| = 0.109）或单独使用时（p = 0.404，|r| = 0.182）则无此效果。在益生菌加非SSRIs组中，随着抑郁症状的改善，异戊酸水平下降。结论：R0052/R0175作为非SSRI抗抑郁药的辅助用药，可能部分通过降低异戊酸水平发挥抗抑郁作用。需要进行更大样本量的研究，以进一步探讨SCFAs作为益生菌和药物抗抑郁作用介质的作用。ClinicalTrials.gov标识符：NCT04756544。
